Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Carmen Garnacho"'
Autor:
Carmen Garnacho, Silvia Muro
Publikováno v:
Journal of Drug Targeting. 25:786-795
Enzyme replacement is a viable treatment for diseases caused by genetic deficiency of lysosomal enzymes. However, suboptimal access of enzymes to target sites limits this strategy. Polymer nanocarriers (NCs) coated with antibody against intercellular
Autor:
Carmen Garnacho
Publikováno v:
Scopus-Elsevier
Over the last half century, the delivery of pharmacologically active substances, such as synthetic drugs, natural compounds, gene material and many other pharmaceutical products, has been widely studied. Understanding the interactions of drug carrier
A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders
Publikováno v:
Molecular Pharmaceutics. 13:357-368
Many cellular activities and pharmaceutical interventions involve endocytosis and delivery to lysosomes for processing. Hence, lysosomal processing defects can cause cell and tissue damage, as in lysosomal storage diseases (LSDs) characterized by lys
Publikováno v:
Molecular Pharmaceutics. 12:1366-1376
Pharmaceutical intervention often requires therapeutics and/or their carriers to enter cells via endocytosis. Therefore, endocytic aberrancies resulting from disease represent a key, yet often overlooked, parameter in designing therapeutic strategies
Publikováno v:
Molecular Pharmaceutics
Drugs often use endocytosis to achieve intracellular delivery, either by passive uptake from the extracellular fluid or by active targeting of cell surface features such as endocytic receptors. An example is enzyme replacement therapy, a clinically p
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy. 25(7)
Acid sphingomyelinase deficiency in type B Niemann-Pick disease leads to lysosomal sphingomyelin storage, principally affecting lungs, liver, and spleen. Infused recombinant enzyme is beneficial, yet its delivery to the lungs is limited and requires
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 32:1178-1185
Objective— Engagement of intercellular adhesion molecule 1 (ICAM-1) on endothelial cells by ICAM-1-targeted carriers induces cell adhesion molecule–mediated endocytosis, providing intraendothelial delivery of therapeutics. This pathway differs fr
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 340:638-647
Intercellular adhesion molecule-1 (ICAM-1), a transmembrane glycoprotein expressed on activated endothelium and many other cells, represents a suitable target for delivery of drug nanocarriers (NCs) to disease areas. Numerous works have shown efficie
Autor:
Yang Shen, Tridib Kumar Bhowmick, Carmen Garnacho, Daniel Serrano, Janet Hsu, Yuan-Chia Kuo, Silvia Muro, Kishan Kumar
Publikováno v:
Journal of Controlled Release. 149:323-331
Fabry disease, due to the deficiency of α-galactosidase A (α-Gal), causes lysosomal accumulation of globotriaosylceramide (Gb3) in multiple tissues and prominently in the vascular endothelium. Although enzyme replacement therapy (ERT) by injection
Publikováno v:
Journal of Controlled Release. 130:226-233
Coupling drug carriers to antibodies for targeting endothelial cells (ECs) may improve treatment of vascular and pulmonary diseases. Selecting antibodies that deliver carriers to the cell surface or intracellularly may further optimize specificity of